Page last updated: 2024-11-05

tripelennamine and Lipidoses

tripelennamine has been researched along with Lipidoses in 2 studies

Tripelennamine: A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat ASTHMA; HAY FEVER; URTICARIA; and RHINITIS; and also in veterinary applications. Tripelennamine is administered by various routes, including topically.

Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.

Research Excerpts

ExcerptRelevanceReference
"Phospholipidosis is an adverse effect caused by numerous cationic amphiphilic drugs and can affect many cell types."1.36Predicting phospholipidosis using machine learning. ( Glen, RC; Lowe, R; Mitchell, JB, 2010)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lowe, R1
Glen, RC1
Mitchell, JB1
Hostetler, KY1
Matsuzawa, Y1

Other Studies

2 other studies available for tripelennamine and Lipidoses

ArticleYear
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Bio

2010
Studies on the mechanism of drug-induced lipidosis. Cationic amphiphilic drug inhibition of lysosomal phospholipases A and C.
    Biochemical pharmacology, 1981, May-15, Volume: 30, Issue:10

    Topics: Amantadine; Aniline Compounds; Animals; Chlorphentermine; Chlorpromazine; Heptanes; Imipramine; Lipi

1981